Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study
Open Access
- 1 January 2022
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 9 (1) , 26-30
Abstract
Objective: There is no clinically useful biomarker as a predictor of response to any class of biological disease-modifying antirheumatic drugs (bDMARD). Serum interleukin-6 (IL-6) has a major role in the pathogenesis of rheumatoid arthritis (RA) and its serum level in patients of RA may predict response to treatment with IL-6 receptor (IL-6R) antagonist tocilizumab. Methods: Biological DMARD naïve patients of seropositive RA, fulfilling American College of Rheumatology/European League Against Rheumatism classification criteria 2010, were treated with 06 doses of tocilizumab (8mg/kg) at monthly interval. Baseline and post-treatment serum IL-6 levels were measured and correlated with response to treatment measured by disease activity score-28 joints erythrocyte sedimentation rate (DAS28 ESR) after treatment. Results: The study included 34 patients and 26 (70%) of them achieved DAS-28 remission (DAS28 ESR < 2.6). The baseline serum IL-6 did not correlate with post-treatment DAS28 ESR (R −0.197, P = .264). Though, statistically not significant (P = .085) more patients with comparatively lower baseline serum IL-6 attained DAS28 remission (16 out of 17, P = .085). There was an increase in the serum IL-6 level (median 40.5pg/ml [IQR 130.2] to 72.6pg/ml [IQR 162.5]) after tocilizumab treatment and the change in IL-6 level also did not correlate with post-treatment DAS28 ESR (R −0.240, P = .172). Conclusion: Higher number of patients with comparatively lower serum IL-6 level attained DAS28 remission in this study; however, it was not statistically significant. It requires further evaluation in larger studies to make any conclusion on the role of serum IL-6 as a predictor of response to tocilizumab in seropositive RA. Cite this article as: Kumar A, Bhakuni DS, Kartik S, et al. Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study. Eur J Rheumatol. 2021;9(1):26-30.Keywords
This publication has 19 references indexed in Scilit:
- Optimising treatment in rheumatoid arthritis: a review of potential biological markers of responseAnnals of the Rheumatic Diseases, 2011
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patientsArthritis & Rheumatism, 2007
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α InhibitionNew England Journal of Medicine, 2005
- Relationships between local inflammation, interleukin‐6 concentration and the acute phase protein response in arthritis patientsEuropean Journal of Clinical Investigation, 1991
- Rheumatoid ArthritisNew England Journal of Medicine, 1990
- Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130Cell, 1989
- Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritisEuropean Journal of Immunology, 1988